ZURA - Zura Bio Limited Analyst Consensus Forecast
Zura Bio Limited (ZURA) is accelerating the development of immunological agents through alliances with specialized laboratories and the joint pursuit of new therapeutic methods. The quotes provided below, recorded at 8.34, complement the profile of this biotech firm, which attracts leading immunologists with a flexible corporate culture and generous stock options. High investor confidence is driven by management's deep expertise during a period of active clinical deployment following the funding round.
Analytical breakdowns for Zura Bio (ZURA)
- share price and expert price forecast:
- market capitalization statistics:
- balance sheet equity data:
- issuer credit burden and liquidity indicators:
Aggregate Debt to Equity Zura Bio Limited|ZURA - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Zura Bio Ltd|ZURA - Company Aggregate Debts|Debts to Book Capitalization Zura Bio Limited|ZURA - Company Long-Term Debt|Company Short-Term Loans and Borrowings Zura Bio|Quick Liquidity Indicator zurabio.com
- earnings and valuation multiples information:
ZURA - Net Profit|Projected Future Earnings Zura Bio Limited|ZURA - Price to Earnings Ratio|Future Price to Earnings Multiple zurabio.com|ZURA - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Zura Bio Limited|ZURA - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Zura Bio|ZURA - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months zurabio.com|ZURA - Net earnings per share growth this year|Earnings growth forecast for next year Zura Bio Limited
General company analysis:ZURA zurabio.com
The innovative potential of Zura Bio Limited immune drugs is facing geopolitical barriers in biomaterial logistics, which directly impacts the dynamics of the current market consensus target. This indicator represents the arithmetic mean of target prices from industry experts, and the current value of 8.34 serves as a fundamental benchmark for the stock's fair value, allowing investors to assess the degree of overpayment when purchasing the asset.
Competitors of Zura Bio Limited
ARGX: Forecast Levels Chart|BioNTech - Consensus Target|Analyst Consensus Forecast Abivax SA ABVX|ADMA - Price Target Chart|Fair Value Consensus PTGX (Protagonist Corp)|IMVT: Analyst Consensus Forecast|kiniksa.com (KNSA) - Analyst Consensus Forecast|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|JBIO: Consensus Target|Forecast Levels Chart ACRS|KYTX (Kyverna Therapeutics) - Consensus Target|tizianalifesciences.com (TLSA) - Analyst Consensus Forecast|Price Target Chart Cabaletta Bio|VTYX: Fair Value Consensus|Analyst Consensus Forecast THTX|Analyst Consensus Forecast Avalo Therapeutics Inc (AVTX)|Eledon Pharmaceuticals - Consensus Target|Fair Value Consensus AGEN|Climb Bio - Analyst Consensus Forecast|ATYR: Price Target Chart|ADAG: Analyst Consensus Forecast|IMA - Analyst Median Target|Price Target Chart Shattuck Labs Inc|Average Forecast Price Equillium Bio EQ|Consensus Target CNTB (Connect Biopharma)|IMUX (immunic-therapeutics.com) - Fair Value Consensus|Price Target Chart Atara Bio ATRA|InflaRx NV - Price Target Chart|X4 Pharmaceuticals - Analyst Consensus Forecast|Analyst Median Target Adicet Bio ACET|celularity.com (CELU) - Price Target Chart|Consensus Target INmune Bio Inc|BRNS (Barinthus Bio) - Analyst Consensus Forecast|Kezar Life Sciences Inc (KZR) - Analyst Median Target|Consensus Target SABS (SAB Biotherapeutics)|Analyst Forecast Prices AKTX|Analyst Consensus Forecast ENLV (Enlivex Therapeutics Ltd.)|Q32 Bio Inc (QTTB) - Average Forecast Price|GeoVax Labs Inc - Analyst Consensus Forecast|EDSA (Edesa Biotech Corp) - Broker Consensus Forecast|IBIO (iBio, Inc.) - Consensus Target|Forecast Levels Chart CARM (Carisma Therapeutics Inc.)|Consensus Target XTLB|Analyst Consensus Forecast Bolt Bio|Price Target Chart HCW Biologics Inc. (HCWB)|APVO (aptevotherapeutics.com) - Fair Value Consensus|Analyst Consensus Forecast AIM (AIM ImmunoTech)|Analyst Consensus Forecast Aditxt Inc. ADTX|GRI - Price Target Chart|Forecast Levels Chart XRTX|HIND: Analyst Consensus Forecast|Revelation Biosciences Corp - Fair Value Consensus|INDP (Indaptus Therapeutics) - Analyst Consensus Forecast|Analyst Consensus Forecast scinai.com|Price Target Chart CalciMedica, Inc. (CALI)|AFMD (affimed.com) - Fair Value Consensus|Price Target Chart Allakos ALLK|HOOK - Consensus Target|IGM Bio - Analyst Consensus Forecast|ITOS - Analyst Consensus Forecast|OCEA (Ocean Biomedical) - Consensus Target|TC BioPharm (Holdings) Plc - Fair Value Consensus|THRD (Third Harmonic Bio, Inc) - Analyst Consensus Forecast
